Prosecution Insights
Last updated: October 04, 2026
Application No. 18/628,035

METHOD FOR MANAGING BREAST MILK EXPRESSION

Final Rejection §102
Filed
Apr 05, 2024
Examiner
HAYMAN, IMANI N
Art Unit
Tech Center
Assignee
Medela AG
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
9m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
523 granted / 730 resolved
+11.6% vs TC avg
Strong +25% interview lift
Without
With
+25.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
6 currently pending
Career history
731
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
46.9%
+6.9% vs TC avg
§102
28.6%
-11.4% vs TC avg
§112
17.1%
-22.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 730 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Acknowledgements In response to the Amendment filed 8/25/2026, claims 1, 14-15 are amended. The 112(b) rejection set forth in the previous Office Action is withdrawn due to Applicant’s amendment. Claims 1-15 are pending. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-2, 8-10, 14, 15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 20170072118 to Makower. As to claim 1, Makower discloses a method for managing breast milk expression [0203] comprising: providing an expected milk yield over time (figures 30 and 32); expressing milk and measuring the expressed milk yield at a given time [0195; 0197]; comparing the measured milk yield at the given time with the expected milk yield at the given time [0199; 0206]; and generating an alarm if the measured milk yield is lower than the expected yield (claim 7). As to claim 2, Makower discloses the method of claim 1, wherein the expected milk yield is provided with reference to a baby birth, and a measured milk yield is measured with reference to the baby birth [0199]. As to claim 8, Makower discloses the method of claim 1, wherein the method is implemented by a software executed by a processor of a smartphone or tablet or computer [0196-0197]. As to claim 9, Makower discloses the method of claim 1, wherein the method is implemented by a software executed by a processor of a controller of a breast pump [0196-0197]. As to claim 10, Makower discloses the method as defined in claim 8, wherein the software outputs information on the daily yield over time together with a path of expected yield over a time [0198]. As to claim 14, Makower discloses a software comprising instructions that, when executed by at least one programmable processor, cause the at least one programmable processor to provide an expected milk yield over time (figures 30 and 32); express milk and measure the expressed milk yield at a given time [0195; 0197]; compare the measured milk yield at the given time with the expected milk yield at the given time [0199; 0206]; and generate an alarm if the measured milk yield is lower than the expected yield (claim 7). As to claim 15, Makower discloses a breast pump comprising an aggregate (30) and a controller (52), the controller associated with the programmable processor (1604) that executes the software according to claim 14. Allowable Subject Matter Claims 3-7, 11-13 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Arguments Applicant's arguments filed 8/25/2026 have been fully considered but they are not persuasive. In response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., an expected milk yield of the user) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Claim 1 as amended requires “providing an expected milk yield over time; expressing milk and measuring the expressed milk yield at a given time; comparing the measured milk yield at the given time with the expected milk yield at the given time; and generating an alarm if the measured milk yield is lower than the expected yield.” Examiner maintains Makower discloses the limitations as rejected above. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IMANI N HAYMAN whose telephone number is (571)270-5528. The examiner can normally be reached 5:30 AM - 3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /IMANI N HAYMAN/Supervisory Patent Examiner, Art Unit 2841
Read full office action

Prosecution Timeline

Apr 05, 2024
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §102
Aug 25, 2026
Response Filed
Sep 15, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12721974
Cannula tip protector
2y 9m to grant Granted Sep 01, 2026
Patent 12713566
ELECTRONIC CONTROL UNIT
3y 4m to grant Granted Aug 18, 2026
Patent 12708721
Adaptor for a Drug Delivery Device and Drug Delivery Device
2y 9m to grant Granted Aug 18, 2026
Patent 12623033
Safety Device for Shielding an Injection Needle of a Medical Container, and an Injection Device Including This Safety Device
3y 4m to grant Granted May 12, 2026
Patent 12599746
CUFFED AND NON-CUFFED DIALYSIS CATHETER SYSTEMS AND METHODS
3y 8m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
97%
With Interview (+25.4%)
3y 3m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 730 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month